Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: The LIPID study

Funke-Kaiser, Anne; Mann, K.; Colquhoun, David; Zeller, Tanja; Hunt, David; Simes, John; Sullivan, David; Sydow, Karsten; West, Malcolm; White, Harvey D.; Blankenberg, Stefan; Tonkin, Andrew

doi:10.1016/j.ijcard.2014.01.064

Cited by 12 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 Baseline and the change in MR-proADM concentrations after ACS have been shown to be associated with risk of major clinical events, including death. 23 In this study, we assessed the utility of MR-proADM compared with cardiac troponin I (cTnI) for prediction of mortality and major adverse cardiac events (MACE) in an undifferentiated cohort of patients presenting to the ED with chest pain.…”

Section: Discussionmentioning

confidence: 99%

Midregional Proadrenomedullin Predicts Mortality and Major Adverse Cardiac Events in Patients Presenting With Chest Pain: Results From the CHOPIN Trial

Shah

Marston

Müeller

et al. 2015

Academic Emergency Medicine

View full text Add to dashboard Cite

Objectives: Chest pain is a common complaint to emergency departments (EDs) and clinical risk factors are used to predict which patients are at risk for worse outcomes and mortality. The goal was to assess the novel biomarker midregional proadrenomedullin (MR-proADM) in prediction of mortality and major adverse cardiac events (MACE).Methods: This was a subanalysis of the CHOPIN study, a 16-center prospective trial that enrolled 2,071 patients presenting with chest pain within 6 hours of onset. The primary endpoint was 6-month all-cause mortality and the secondary endpoint was 30-day and 6-month MACE: ED visits or hospitalization for acute myocardial infarction, unstable angina, reinfarction, revascularization, and heart failure.Results: MR-proADM performed similarly to troponin (cTnI; c-statistic = 0.845 and 0.794, respectively) for mortality prediction in all subjects and had similar results in those with noncardiac diagnoses. MRproADM concentrations were stratified by decile, and the cohort in the top decile had a 9.8% 6-month mortality risk versus 0.9% risk for those in the bottom nine deciles (p < 0.0001). MR-proADM, history of coronary artery disease (CAD), and hypertension were predictors of short-term MACE, while history of CAD, hypertension, cTnI, and MR-proADM were predictors of long-term MACE.

show abstract

Section: Discussionmentioning

confidence: 99%

Midregional Proadrenomedullin Predicts Mortality and Major Adverse Cardiac Events in Patients Presenting With Chest Pain: Results From the CHOPIN Trial

Shah

Marston

Müeller

et al. 2015

Academic Emergency Medicine

View full text Add to dashboard Cite

show abstract

“…MR-proADM concentration regardless of age was also observed in the von Haehling and Lim studies [ 5 , 6 ] . On the other hand, other studies tend to have higher MR-proADM values in older people [ 7 - 9 ] .…”

Section: Discussionmentioning

confidence: 93%

“…Similar observations were made by Holmanger [ 14 ] . Diabetes was a predictor of higher MR-proADM concentration in the Leicester Acute Myocardial Infarction Peptide (or LAMP) and Long-term Intervention with Pravastatin in Ischaemic Disease (or LIPID) studies [ 8 , 9 ] .…”

Section: Discussionmentioning

confidence: 99%

Proadrenomedullin in Patients with Preserved Left Ventricular Systolic Function Undergoing Coronary Artery Bypass Grafting

Stanisz-Kempa¹,

Gąsior²,

Kułach³

2022

Braz J Cardiovasc Surg

View full text Add to dashboard Cite

Introduction A potentially new marker of cardiovascular diseases — proadrenomedullin is the precursor of adrenomedullin, which is a multifunctional peptide hormone, produced in most of the tissues in response to cellular stress, ischemia, and hypoxia. Methods Ninety-three people, aged 51-79 years, were included in the study. Exclusion criteria were severe or corrected valvular disease, acute coronary syndrome, age ≥ 80 years, glomerular filtration rate < 45 ml/min, active infectious diseases, and cancer. The subjects were observed for adverse events, including reduced left ventricular ejection fraction (LVEF) by ≥ 10%, first incidence of atrial fibrillation (AF), and the necessity of using dopamine during hospitalization. Results Use of pressure amines, occurrence of the first AF episode, and left ventricular dysfunction defined by a decrease in LVEF by at least 10% compared to the value before surgery were reported in the perioperative period. No death, sudden cardiac arrest with effective resuscitation, non-ST-elevation myocardial infarction, ST-elevation myocardial infarction, or heart failure were observed. Significantly higher proadrenomedullin concentration was observed in the group with reduced postoperative LVEF (1.68 vs . 0.77 nmol/l, P =0.005). The relative risk of a decrease in ejection fraction in the group of patients with proadrenomedullin concentration ≥ 0.77 nmol/l was more than twelve-fold higher (95% confidence interval 1.69-888.33; P =0.013) than in the group of patients with a concentration of proadrenomedullin < 0.77 nmol/l. Conclusion The higher baseline concentration of proadrenomedullin has a predominantly predictive value of postoperative left ventricular systolic dysfunction.

show abstract

“…Biomarkers, which we define as biological factors measured in blood samples, may also serve as prognostic factors. In HF, the prognostic abilities of many biomarkers [ 21 – 25 ] have been investigated [ 22 , 26 ]. Sometimes, multiple factors are combined into a prognostic model.…”

Section: Introductionmentioning

confidence: 99%

“…Although some prognostic models focus on patient characteristics that are common or easy to obtain (e.g. age, gender, blood pressure levels), several studies have suggested that biomarkers such as adrenomedullin [ 21 ], high-sensitive cardiac troponin T (hs-cTnT) [ 22 ], cardiac troponin [ 23 ], soluble suppression of tumorigenicity-2 (sST2) [ 24 ], and galectin-3 [ 25 ] substantially improve their predictive performance. For this reason, prognostic models that require information on biomarkers are increasingly common in predicting clinical HF outcomes such as mortality, re-hospitalization, or advanced treatment (e.g.…”

Section: Introductionmentioning

confidence: 99%

UMBRELLA protocol: systematic reviews of multivariable biomarker prognostic models developed to predict clinical outcomes in patients with heart failure

et al. 2020

View full text Add to dashboard Cite

Background Heart failure (HF) is a chronic and common condition with a rising prevalence, especially in the elderly. Morbidity and mortality rates in people with HF are similar to those with common forms of cancer. Clinical guidelines highlight the need for more detailed prognostic information to optimise treatment and care planning for people with HF. Besides proven prognostic biomarkers and numerous newly developed prognostic models for HF clinical outcomes, no risk stratification models have been adequately established. Through a number of linked systematic reviews, we aim to assess the quality of the existing models with biomarkers in HF and summarise the evidence they present. Methods We will search MEDLINE, EMBASE, Web of Science Core Collection, and the prognostic studies database maintained by the Cochrane Prognosis Methods Group combining sensitive published search filters, with no language restriction, from 1990 onwards. Independent pairs of reviewers will screen and extract data. Eligible studies will be those developing, validating, or updating any prognostic model with biomarkers for clinical outcomes in adults with any type of HF. Data will be extracted using a piloted form that combines published good practice guidelines for critical appraisal, data extraction, and risk of bias assessment of prediction modelling studies. Missing information on predictive performance measures will be sought by contacting authors or estimated from available information when possible. If sufficient high quality and homogeneous data are available, we will meta-analyse the predictive performance of identified models. Sources of between-study heterogeneity will be explored through meta-regression using pre-defined study-level covariates. Results will be reported narratively if study quality is deemed to be low or if the between-study heterogeneity is high. Sensitivity analyses for risk of bias impact will be performed. Discussion This project aims to appraise and summarise the methodological conduct and predictive performance of existing clinically homogeneous HF prognostic models in separate systematic reviews. Registration: PROSPERO registration number CRD42019086990

show abstract

Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: The LIPID study

Cited by 12 publications

References 29 publications

Midregional Proadrenomedullin Predicts Mortality and Major Adverse Cardiac Events in Patients Presenting With Chest Pain: Results From the CHOPIN Trial

Midregional Proadrenomedullin Predicts Mortality and Major Adverse Cardiac Events in Patients Presenting With Chest Pain: Results From the CHOPIN Trial

Proadrenomedullin in Patients with Preserved Left Ventricular Systolic Function Undergoing Coronary Artery Bypass Grafting

UMBRELLA protocol: systematic reviews of multivariable biomarker prognostic models developed to predict clinical outcomes in patients with heart failure

Contact Info

Product

Resources

About